heard on the application for this withdrawal extension must submit a written request to the State Director, BLM Oregon/Washington State Office at the address in the **ADDRESSES** section, within 90 days from the date of publication of this notice. If the authorized officer determines that a public meeting will be held, a notice of the date, time, and place will be published in the **Federal Register** and local newspapers and posted on the BLM website at: *www.blm.gov* at least 30 days before the scheduled date of the meeting. This withdrawal extension application will be processed in accordance with the regulations set forth in 43 CFR 2310.4.

(Authority: 43 CFR 2310.3–1.)

Dustin Webster-Wharton,

Branch Chief, Lands, Minerals, Energy Resources—Acting.

[FR Doc. 2023–02464 Filed 2–3–23; 8:45 am]

BILLING CODE 3410–15–P

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[BLM_AK_FRN_MO4500168906]

Notice of Availability of the Final Supplemental Environmental Impact Statement for the Willow Master Development Plan, Alaska

AGENCY: Bureau of Land Management, Interior.

ACTION: Notice of Availability.

SUMMARY: In accordance with the National Environmental Policy Act of 1969, as amended, the Bureau of Land Management (BLM) has prepared a Final Supplemental Environmental Impact Statement (EIS) for the Willow Master Development Plan (MDP), and by this notice is announcing its publication.

DATES: The BLM will issue a Record of Decision (ROD) for the project no earlier than 30 days from the date the Environmental Protection Agency publishes its Notice of Availability of the Final Supplemental EIS in the **Federal Register**.

ADDRESSES: To access the Final Supplemental EIS please visit the project's National Environmental Policy Act (NEPA) Register website:

- BLM's NEPA Register website: *https://eplanning.blm.gov/eplanning-ui/project/109410/510*

To request an electronic or paper copy of the Final SEIS, please reach out to:

- *Mail:* 222 W. 7th Avenue, Stop #13, Anchorage, Alaska 99513

Documents pertinent to this proposal, including the Draft SEIS, may be examined at the NEPA Register website. *https://eplanning.blm.gov/eplanning-ui/project/109410/510*

FOR FURTHER INFORMATION CONTACT: Carrie Cecil at (907) 271–1306, or by email at *ccecil@blm.gov,* on questions specific to NEPA or to have your name added to our mailing list. Individuals in the United States who are deaf, blind, hard of hearing, or have a speech disability may dial 711 (TTY, TDD, or TeleBraille) to access telecommunications relay services. Individuals outside the United States should use the relay services offered within their country to make international calls to the point-of-contact in the United States.

SUPPLEMENTARY INFORMATION: The Willow Master Development Plan Final Supplemental EIS analyzes an oil and gas development project proposed by ConocoPhillips Alaska, Inc. on Federal oil and gas leases it holds in the northeast region of the National Petroleum Reserve in Alaska. The Willow project was originally analyzed in the 2020 Willow MDP/Final EIS and authorized in a ROD issued in October 2020. In August 2021, the U.S. District Court for the District of Alaska vacated the ROD and remanded the matter to BLM to correct deficiencies in the EIS regarding analysis of foreign greenhouse gas emissions and screening of alternatives for detailed analysis. To comply with this ruling, the BLM made numerous updates to the analysis, including development of a new alternative (Alternative E) that substantially reduces infrastructure in the Teshekpuk Lake Special Area. The BLM has identified Alternative E and Module Delivery Option 3 as its preferred alternative. The Draft Supplemental EIS was issued on July 15, 2022, with opportunity for public comment. This Final Supplemental EIS complies with all applicable laws and current Department of the Interior guidance, including (but not limited to) NEPA, the Federal Land Policy and Management Act of 1976, the Alaska National Interest Lands Conservation Act, and the Naval Petroleum Reserves Production Act.

Authority: 40 CFR 1506.6(b).

Steven Cohn,

State Director, BLM Alaska.

[FR Doc. 2023–02344 Filed 2–3–23; 8:45 am]

BILLING CODE 4331–10–P

DEPARTMENT OF INTERIOR

National Park Service

[NPS–IMR–BIBE–34285; PPIMBIBES0, PPMPSPD1Z.YM]

Determination of Eligibility for Consideration as Wilderness Areas, Big Bend National Park

AGENCY: National Park Service, Interior.

ACTION: Notice of Determination of Wilderness Eligibility for Lands in Big Bend National Park.

SUMMARY: Pursuant to the Wilderness Act of 1964, and in accordance with National Park Service (NPS) *Management Policies 2006* (MP 2006), Section 6.2.1, the NPS has completed a Wilderness Eligibility Assessment to determine if lands within the North Rosillos (Harte Ranch) section of Big Bend National Park meet criteria indicating eligibility for preservation as wilderness. The NPS has concluded that 63,505 acres of the 67,135 acres assessed are found to be eligible for inclusion in the wilderness preservation system because they have wilderness criteria described in the Wilderness Act of 1964. This acreage represents 7.9% of the park's total 801,365 acres.

ADDRESSES: Maps of the lands assessed are on file at Big Bend National Park Headquarters, 1 Alsate Drive, Big Bend National Park, Texas.

FOR FURTHER INFORMATION CONTACT: Superintendent Bob Krumenaker, Big Bend National Park Superintendent, P.O. Box 129, Big Bend National Park, TX 79834. Phone (432) 477–1102, Email *bob_krumenaker@nps.gov.*

SUPPLEMENTARY INFORMATION: The Big Bend National Park staff reviewed the Primary Eligibility Criteria, Section 6.2.1.1 of MP 2006 to evaluate the wilderness eligibility of the North Rosillos area, which was authorized in 1980 to be added to the national park. All of the lands within the expanded boundary were assessed except for one large inholding of approximately 25,000 acres. Of the park's original 700,000 acres, 538,250 acres within the park had been recommended to U.S. Congress for formal wilderness designation in 1978 (67% of the park), and an additional 44,750 acres were recommended for potential wilderness (6% of the park).

Public notices announcing the park's intention to conduct this assessment were placed in the **Federal Register** May 3, 2000, and public meetings that were announced by mailings and newsletters were conducted in four Texas communities in May, 2000. While a draft memo called a Wilderness

Suitability Assessment was included as an appendix to the park's 2004 General Management Plan, the Assessment remained unfinished until 2022.

NPS will take no action that would diminish the wilderness eligibility of the area found to be possessing wilderness characteristics until the legislative process of wilderness designation has been completed, as required by Chapter 6 of MP 2006. All of the assessed lands remain subject to management in accordance with the NPS Organic Act and all other laws, Executive orders, regulations, and policies applicable to units of the National Park System; the 3,636 acres of ineligible lands will not be subject to the additional requirements of MP 2006 Chapter 6.

If/when a formal wilderness study is conducted to determine which of the eligible lands, if any, should be proposed for inclusion in the National Wilderness Preservation System, tribal consultation will be initiated, as will public review and comment under NEPA and the National Historic Preservation Act.

Charles F. Sams, III,

Director, National Park Service.

[FR Doc. 2023–02469 Filed 2–3–23; 8:45 am]

BILLING CODE 4312–52–P

INTERNATIONAL TRADE COMMISSION

[Investigation No. 332–596]

COVID–19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities

AGENCY: United States International Trade Commission.

ACTION: Notice of investigation and scheduling of a public hearing.

SUMMARY: Following receipt on December 16, 2022, of a request from the U.S. Trade Representative (USTR), under the Tariff Act of 1930, the U.S. International Trade Commission (Commission) instituted Investigation No. 332–596, *COVID–19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities.* The USTR requested that the Commission conduct an investigation and prepare a report that analyzes the universe of existing COVID–19 diagnostics and therapeutics in relation to the World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement)—including the range of definitions for diagnostics and therapeutics; diagnostics and therapeutics covered by patents and those in development; an overview of production, distribution, and demand; information on market segmentation of global demand and consumption; and other information relevant to the discussion of TRIPS Agreement flexibilities.

DATES:

March 15, 2023: Deadline for filing requests to appear at the public hearing.

March 17, 2023: Deadline for filing prehearing briefs and statements.

March 22, 2023: Deadline for filing electronic copies of oral hearing statements.

March 29–30, 2023: Public hearing.

April 12, 2023: Deadline for filing posthearing briefs and statements.

May 5, 2023: Deadline for filing all other written submissions.

October 17, 2023: Transmittal of Commission report to the USTR.

ADDRESSES: All Commission offices, including the Commission's hearing rooms, are located in the U.S. International Trade Commission Building, 500 E Street SW, Washington, DC. All written submissions should be addressed to the Secretary, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436. The public record for this investigation may be viewed on the Commission's electronic docket (EDIS) at *https://edis.usitc.gov.*

FOR FURTHER INFORMATION CONTACT: Project Leader Philip Stone (202–205–3424 or *philip.stone@usitc.gov*) or Deputy Project Leader Dixie Downing (202–205–3164 or *dixie.downing@usitc.gov*) for information specific to this investigation. For information on the legal aspects of this investigation, contact Brian Allen (202–205–3034 or *brian.allen@usitc.gov*) or William Gearhart (202–205–3091 or *william.gearhart@usitc.gov*) of the Commission's Office of the General Counsel. The media should contact Jennifer Andberg, Office of External Relations (202–205–3404 or *jennifer.andberg@usitc.gov*). Hearing-impaired individuals are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on 202–205–1810. General information concerning the Commission may be obtained by accessing its internet address (*https://www.usitc.gov*). Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at 202–205–2000.

SUPPLEMENTARY INFORMATION:

Background: As requested in the letter received from the USTR on December 16, 2022, the Commission has instituted an investigation under section 332(g) of the Tariff Act of 1930 (19 U.S.C. 1332(g)) that analyzes the universe of existing COVID–19 diagnostics and therapeutics in relation to the TRIPS Agreement. Specifically, the USTR has requested that the Commission prepare a report that:

- Identifies the range of definitions for ''diagnostics'' and ''therapeutics'' in the medical field.
- Identifies and defines the universe of existing COVID–19 diagnostics and therapeutics covered by patents as well as COVID–19 diagnostics and therapeutics in development.
- Provides a broad overview of relevant COVID–19 diagnostics and therapeutics, including a description of the products and any intellectual property protections, and containing, to the extent practicable and where data are available:
  - An overview of production and distribution, including key components, the production processes, key producing countries, major firms, operational costs, a description of the supply chain, and the level of geographic diversification within the supply chain;
  - An overview of demand, including key demand factors, an assessment of where unmet demand exists, supply accumulation and distribution, and the impact of the relationship between testing and demand for treatment, if any exists;
  - Information on market segmentation of global demand and consumption, which may be delineated by low-income countries (LICs), lower middle-income countries (LMICs), upper middle-income countries (UMICs), and high-income countries (HICs);
  - Information on availability and pricing (or manufacturing costs in the cases where goods are donated) for COVID–19 diagnostics and therapeutics, if available; and
  - Global trade data for COVID–19 diagnostics and therapeutics or diagnostics and therapeutics in general if specific data are not available.
- Catalogs, to the extent practicable based on available information and a critical review of the literature:
  - The reasons for market segmentation and barriers to a more diverse geographical distribution of the global manufacturing industries for COVID–19 diagnostics and therapeutics;
  - The relationship between patent protection and innovation in the health sector and between patent protection and access to medicine in LICs, LMICs, UMICs, and HICs;
  - Actions taken by WTO Members to use or attempt to use compulsory